Report Overview

The EU Ophthalmology Drugs & Device market size stood at round USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5.3% during the forecast period

Ophthalmology is a branch of medicine dealing with the diagnosis, treatment and prevention of diseases of the eye and visual system. The eye, its surrounding structures and the visual system can be affected by a number of clinical conditions. Ophthalmology involves diagnosis and therapy of such conditions, along with microsurgery. Eye health services are becoming more and more important as the UK population ages. An ageing population means there are more and more incidences of age-related diseases of the eye, such as age-related macular degeneration. These eye diseases can be successfully treated if caught early, and can be managed effectively with existing treatments and medicines



Market Drivers

The European ophthalmology drug and device market is expected to witness significant growth in the forthcoming years, as multiple manufacturers are increasingly focusing on R&D to develop innovative treatments. The regional players are engaging in extensive R&D activities to develop novel ophthalmic drugs for the treatment of various eye diseases and disorders and to gain a greater market share. In addition, a large number of eye problems, availability of new and advanced devices, and patient preference for non-invasive treatment are also expected to drive the market in the future. Drug delivery systems in ophthalmic therapy undergone major technological advancements in the recent years, which likely to stimulate the growth of the studied market. However, high risk associated with eye surgery and stringent regulations may hamper the growth of the market